Safety and antitumor activity of acalabrutinib for relapsed/refractory B‐cell malignancies: A Japanese phase I study

This multicenter, open‐label, phase I study assessed the safety and antitumor activity of acalabrutinib in Japanese patients with relapsed/refractory (r/r) B‐cell malignancies. Parts 1 (dose confirmation) and 2 (dose expansion) of this three‐part study are reported. Treatment was a single dose of 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Izutsu, Koji, Ando, Kiyoshi, Ennishi, Daisuke, Shibayama, Hirohiko, Suzumiya, Junji, Yamamoto, Kazuhito, Ichikawa, Satoshi, Kato, Koji, Kumagai, Kyoya, Patel, Priti, Iizumi, Sakura, Hayashi, Nobuya, Kawasumi, Hisashi, Murayama, Kosho, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177795/
https://www.ncbi.nlm.nih.gov/pubmed/33728735
http://dx.doi.org/10.1111/cas.14886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177795/
https://www.ncbi.nlm.nih.gov/pubmed/33728735
http://dx.doi.org/10.1111/cas.14886

Ejemplares similares